gms | German Medical Science

46. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 32. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

19.09. - 22.09.2018, Mannheim

Association of IgA antibodies against CD74 with production of IL17A but not of TNFa in patients with active axial spondyloarthritis

Meeting Abstract

  • Xenofon Baraliakos - Rheumazentrum Ruhrgebiet, Herne
  • Katja Kniesch - Medizinische Hochschule Hannover, Hannover
  • Niklas Baerlecken - Medizinische Hochschule Hannover, Klinik für Immunologie und Rheumatologie, Hannover
  • Jürgen Braun - Rheumazentrum Ruhrgebiet, Herne
  • Torsten Witte - Medizinische Hochschule Hannover, Klinik für Immunologie und Rheumatologie, Hannover

Deutsche Gesellschaft für Rheumatologie. Deutsche Gesellschaft für Orthopädische Rheumatologie. Gesellschaft für Kinder- und Jugendrheumatologie. 46. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 32. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR). Mannheim, 19.-22.09.2018. Düsseldorf: German Medical Science GMS Publishing House; 2019. DocSpA.05

doi: 10.3205/18dgrh155, urn:nbn:de:0183-18dgrh1557

Veröffentlicht: 5. Februar 2019

© 2019 Baraliakos et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Background: Axial spondyloarthritis (axSpA) is strongly associated with HLA-B27. Recently, IgA antibodies (Abs) against CD74 (IgA-anti-CD74) and T-cells carrying CD-74-specific T-cell receptors were also found to be associated with axSpA, especially in patients with ankylosing spondylitis, the radiographic form of axSpA. Tumor necrosis alpha (TNFa) inhibitors and IL-17 antagonists are efficacious in patients with active axSpA. Herewe investigate whether IgA-anti-CD74 Abs are associated with pro-inflammatory cytokines in the sera of patients with HLA-B27-positive and -negative patients with active axSpA.

Methods: Blood samples of 62 HLA-B27-positive and 58 HLA-B27-negative patients with axSpA (44% AS) prior to starting a biologic therapy were collected. A cytometric bead-array (CBA Flex Set) was used to measure serum levels of interleukin (IL)-17A, IL-6, IL-1α, TNFa, and interferon (INF)-γ. IgA-anti-CD74 Abs were measured by ELISA, using the predefined cut-off of 15 U/ml. Their mean concentrations were compared between groups using T-tests. The patients who were positive or negative for IgA-anti-CD74 Abs were compared using chi-square test.

Results: IgA-anti-CD74 Abs were detected in 54/120 axSpA patients (45%). There were no differences in the baseline demographics and clinical assessments in patients with or without IgA-anti-CD74 Abs. The presence of IgA-anti-CD74 Abs was associated with serum concentrations of IL-17A (p=0.01) (Figure 1 [Fig. 1]), irrespective of the presence of HLA-B27, CRP and IL-6 (both p<0.05) (Figure 2 [Fig. 2]), but not TNFa(p=0.2) (Figure 3 [Fig. 3]).

Conclusion: In a cross-sectional study, the presence of IgA Abs against CD74 was associated with serum levels of pro-inflammatory biomarkers such as CRP (and IL-6) and IL-17 but not TNFa irrespective of HLAB27 status. Longitudinal prospective studies are needed to show that the measurement of IgA anti-CD74 Abs and/or serum cytokines can help to guide treatment decisions.